Reports and Briefs on Therapy Area in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | 3 | 4 | 5 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Market and Product Forecasts: Systemic Lupus Erythematosus – Benlysta approval kicks off new era in lupus treatment

Benlysta’s US and EU approvals will change the lupus market considerably. With additional products moving through the pipeline, Datamonitor expects to see a significant shift from off- to on-label treatment over the next 10 years.

Published By Datamonitor
22 Aug 2011 $6400
Buy
Report
Report

Prescribing Influences: Multiple Sclerosis - Therapies that reverse neuronal damage are most sought after

This report analyzes the unmet needs of multiple sclerosis treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
09 Aug 2011 $2800
Buy
Report
Report

Key Companies: Depression - Leading players must adapt to remain competitive

This report identifies the leading players that are active in the depression pharmaceutical market, evaluating trends in corporate strategy and discussing the impact of key recent licensing deals.

Published By Datamonitor
02 Aug 2011 $2800
Buy
Report
Report

Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate

Datamonitor module assesses the current state of the obesity pipeline and trends that will shape its future. Focused on the US, Japan, France, Germany, Italy, Spain, and the UK

Published By Datamonitor
19 Jul 2011 $6400
Buy
Report
Report

Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation

Allergic rhinitis is an established, yet dynamic market. The April 2011 FDA filing of Dymista (azelastine/fluticasone; Meda/Cipla) could bring a new class to the market, while efforts to retain brand share have been seen in monotherapy classes.

Published By Datamonitor
23 Jun 2011 $6400
Buy
Report
Report

Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribers

This report analyzes the unmet needs of Alzheimer’s disease treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
13 Jun 2011 $2800
Buy
Report
Report

Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated market

Primary research-based analysis of the major depressive disorder market, based on a survey of 180 psychiatrists in the US, Japan, and EU. Includes epidemiology, patient segmentation, treatment trends, perception of key brands, and patient outcomes.

Published By Datamonitor
23 Dec 2010 $6400
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $6400
Buy
Report
Report

Pipeline and Commercial Insight: Psoriasis - Established brands challenged by new therapies

Overview of the current and future psoriasis market, providing in-depth analysis of recent events in the market together with 10 year indication specific sales forecasts and profiles of key brands and pipeline products across the seven major markets.

Published By Datamonitor
10 Dec 2010 $6400
Buy
Report
Report

Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

Analysis of the current and future market for drugs treating depression. Includes sales forecasts to 2019 across the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) of key marketed brands, generics, and pipeline products.

Published By Datamonitor
09 Dec 2010 $6400
Buy

« | 1 | 2 | 3 | 4 | 5 | » »|

No help is available.